eCite Digital Repository
Topical application of TAK1 inhibitor encapsulated by gelatin particle alleviates corneal neovascularization
Wang, J-H and Tseng, C-L and Lin, F-L and Chen, J and Hsieh, E-H and Lama, S and Chuang, Y-F and Kumar, S and Zhu, L and McGuinness, MB and Hernandez, J and Tu, L and Wang, P-Y and Liu, G-S, Topical application of TAK1 inhibitor encapsulated by gelatin particle alleviates corneal neovascularization, Theranostics, 12, (2) pp. 657-674. ISSN 1838-7640 (2022) [Refereed Article]
|PDF (Published version)|
© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Rationale: Corneal neovascularization (CoNV) is a severe complication of various types of corneal diseases, that leads to permanent visual impairment. Current treatments for CoNV, such as steroids or anti-vascular endothelial growth factor agents, are argued over their therapeutic efficacy and adverse effects. Here, we demonstrate that transforming growth factor-β (TGF-β)-activated kinase 1 (TAK1) plays an important role in the pathogenesis of CoNV.
Methods: Angiogenic activities were assessed in ex vivo and in vitro models subjected to TAK1 inhibition by 5Z-7-oxozeaenol, a selective inhibitor of TAK1. RNA-Seq was used to examine pathways that could be potentially affected by TAK1 inhibition. A gelatin-nanoparticles-encapsulated 5Z-7-oxozeaenol was developed as the eyedrop to treat CoNV in a rodent model.
Results: We showed that 5Z-7-oxozeaenol reduced angiogenic processes through impeding cell proliferation. Transcriptome analysis suggested 5Z-7-oxozeaenol principally suppresses cell cycle and DNA replication, thereby restraining cell proliferation. In addition, inhibition of TAK1 by 5Z-7-oxozeaenol blocked TNFα-mediated NFκB signalling, and its downstream genes related to angiogenesis and inflammation. 5Z-7-oxozeaenol also ameliorated pro-angiogenic activity, including endothelial migration and tube formation. Furthermore, topical administration of the gelatin-nanoparticles-encapsulated 5Z-7-oxozeaenol led to significantly greater suppression of CoNV in a mouse model compared to the free form of 5Z-7-oxozeaenol, likely due to extended retention of 5Z-7-oxozeaenol in the cornea.
Conclusion: Our study shows the potential of TAK1 as a therapeutic target for pathological angiogenesis, and the gelatin nanoparticle coupled with 5Z-7-oxozeaenol as a promising new eyedrop administration model in treatment of CoNV.
|Item Type:||Refereed Article|
|Keywords:||corneal neovascularization, eye drops, nanoparticle|
|Research Division:||Biomedical and Clinical Sciences|
|Research Group:||Medical biotechnology|
|Objective Division:||Expanding Knowledge|
|Objective Group:||Expanding knowledge|
|Objective Field:||Expanding knowledge in the biomedical and clinical sciences|
|UTAS Author:||Lin, F-L (Dr Fan-Li Lin)|
|UTAS Author:||Lama, S (Mr Suraj Lama)|
|UTAS Author:||Chuang, Y-F (Dr Yu-Fan Chuang)|
|UTAS Author:||Kumar, S (Mr Satheesh Kumar)|
|UTAS Author:||Zhu, L (Ms Linxin Zhu)|
|UTAS Author:||Hernandez, J (Mrs Jessika Hernandez Garcia)|
|UTAS Author:||Liu, G-S (Associate Professor Guei-Sheung Liu)|
|Web of Science® Times Cited:||3|
|Deposited By:||Menzies Institute for Medical Research|
|Downloads:||14 View Download Statistics|
Repository Staff Only: item control page